Search Results

There are 8219402 results for: content related to: Author's reply

  1. Misconceptions regarding the association between Herbalife products and liver-related case reports in Spain

    Pharmacoepidemiology and Drug Safety

    Volume 21, Issue 3, March 2012, Pages: 333–334, Kristy Appelhans, Vasilios Frankos and Andrew Shao

    Version of Record online : 8 MAR 2012, DOI: 10.1002/pds.3203

  2. In reply

    Pharmacoepidemiology and Drug Safety

    Volume 19, Issue 2, February 2010, Page: 205, Yasuyuki Matsushita, Masahiro Sugihara, Junpei Kaburagi, Masumi Ozawa, Mikio Iwashita, Sanae Yoshida, Hanako Saito and Yoko Hattori

    Version of Record online : 25 JAN 2010, DOI: 10.1002/pds.1914

  3. Choosing an appropriate control group for an observational study design

    Pharmacoepidemiology and Drug Safety

    Volume 21, Issue 3, March 2012, Page: 341, Sjoerd T. Nauta and Ron Van Domburg

    Version of Record online : 8 MAR 2012, DOI: 10.1002/pds.3215

  4. Response to the validity and reliability of a signal impact assessment tool: statistical issue to avoid misinterpretation

    Pharmacoepidemiology and Drug Safety

    Volume 25, Issue 10, October 2016, Page: 1217, Leàn Rolfes, Florence van Hunsel and Eugène van Puijenbroek

    Version of Record online : 3 OCT 2016, DOI: 10.1002/pds.4084

  5. Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury

    Pharmacoepidemiology and Drug Safety

    Volume 20, Issue 10, October 2011, Pages: 1080–1087, Gloria Manso, Laureano López-Rivas, M. Esther Salgueiro, Jose M. Duque, Francisco J. Jimeno, Raúl J. Andrade and M. Isabel Lucena

    Version of Record online : 12 JUL 2011, DOI: 10.1002/pds.2180

  6. You have free access to this content
    Letter: retrospective reviews of liver-related case reports allegedly associated with Herbalife present insufficient and inaccurate data – authors' reply

    Alimentary Pharmacology & Therapeutics

    Volume 37, Issue 7, April 2013, Pages: 754–755, K. R. Reddy and C. Bunchorntavakul

    Version of Record online : 5 MAR 2013, DOI: 10.1111/apt.12242

  7. Under-reporting of adverse drug reactions in the elderly

    Pharmacoepidemiology and Drug Safety

    Volume 4, Issue 6, November/December 1995, Pages: 379–380, Annie Fourrier, Anicet Chaslerie, Jean Francoise Dartigues and Bernard Begaud

    Version of Record online : 7 FEB 2006, DOI: 10.1002/pds.2630040609

  8. Letter

    Pharmacoepidemiology and Drug Safety

    Volume 1, Issue 2, March/April 1992, Page: 105, Rene Jean Royer

    Version of Record online : 12 JAN 2006, DOI: 10.1002/pds.2630010209

  9. Did thirst-blockers contribute to the exorbitant number of fatalities during the French 2003 heat wave?

    Pharmacoepidemiology and Drug Safety

    Volume 17, Issue 3, March 2008, Pages: 312–313, Agnès Sommet, Haleh Bagheri, Maryse Lapeyre-Mestre and Jean-Louis Montastruc

    Version of Record online : 25 FEB 2008, DOI: 10.1002/pds.1548

  10. What makes the phenolphthalein still be a safe drug for patients in China?

    Pharmacoepidemiology and Drug Safety

    Volume 24, Issue 5, May 2015, Pages: 555–557, Baofang Liang, Jianmin Zou and Jianwei Su

    Version of Record online : 23 APR 2015, DOI: 10.1002/pds.3777

  11. Did thirst-blockers like angiotensin-converting-enzyme inhibitors, sartans, serotonine-re-uptake-inhibitors, dopamine agonists/antagonists, or atypical neuroleptics contribute to the exorbitant number of fatalities during the French 2003 heat wave?

    Pharmacoepidemiology and Drug Safety

    Volume 16, Issue 11, November 2007, Pages: 1252–1253, Dr Claudia Stöllberger and Josef Finsterer

    Version of Record online : 26 OCT 2007, DOI: 10.1002/pds.1456

  12. Statins and nonsteroidal anti-inflammatory drugs—an analysis of prescription symmetry

    Pharmacoepidemiology and Drug Safety

    Volume 15, Issue 7, July 2006, Pages: 510–511, Louise Silwer, Max Petzold, Jesper Hallas and Cecilia Stålsby Lundborg

    Version of Record online : 3 JUL 2006, DOI: 10.1002/pds.1250

  13. Re: Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations: implications for COX-2 cardiovascular profile

    Pharmacoepidemiology and Drug Safety

    Volume 16, Issue 11, November 2007, Pages: 1253–1254, Tjeerd P. van Staa and J. Parkinson

    Version of Record online : 26 OCT 2007, DOI: 10.1002/pds.1478

  14. Erratum to ‘Epidemiology of potentially inappropriate medication use in elderly patients in Japanese acute care hospitals’ and ‘Clinical prediction rule to identify high-risk inpatients for adverse drug events: the JADE Study’

    Pharmacoepidemiology and Drug Safety

    Volume 22, Issue 11, November 2013, Page: 1245, Takeshi Morimoto, Mio Sakuma and David W. Bates

    Version of Record online : 21 OCT 2013, DOI: 10.1002/pds.3524

  15. Diclofenac: increase of myocardial infarctions at low doses?

    Pharmacoepidemiology and Drug Safety

    Volume 23, Issue 3, March 2014, Pages: 326–328, Kay Brune

    Version of Record online : 4 MAR 2014, DOI: 10.1002/pds.3564

  16. Temporal relationship between multiple drugs and multiple events in patient reports on adverse drug reactions: findings in a pilot study in Japan

    Pharmacoepidemiology and Drug Safety

    Volume 22, Issue 10, October 2013, Pages: 1134–1137, Kiyoshi Kubota, Mitsuhiro Okazaki, Akira Dobashi, Michiko Yamamoto, Masayuki Hashiguchi, Arisa Horie, Ataru Inagaki, Toshiaki Kikuchi and Mayumi Mochizuki

    Version of Record online : 1 OCT 2013, DOI: 10.1002/pds.3490

  17. Letter to the editor

    Cochlear Implants International

    Volume 7, Issue 3, September 2006, Page: 181, José Letort and Alejandra Ullauri

    Version of Record online : 21 AUG 2006, DOI: 10.1002/cii.310

  18. Additional data on citalopram and the risk of sudden cardiac death and ventricular arrhythmia

    Pharmacoepidemiology and Drug Safety

    Volume 21, Issue 3, March 2012, Pages: 331–332, Charles E. Leonard, Warren B. Bilker, Craig Newcomb, Stephen E. Kimmel and Sean Hennessy

    Version of Record online : 8 MAR 2012, DOI: 10.1002/pds.2352

  19. The case for good pharmacovigilance practice

    Pharmacoepidemiology and Drug Safety

    Volume 9, Issue 4, July/August 2000, Pages: 335–336, Ronald H.B. Meyboom

    Version of Record online : 26 SEP 2000, DOI: 10.1002/1099-1557(200007/08)9:4<335::AID-PDS501>3.0.CO;2-S

  20. Safe administration of metronidazole in a patient with G6PD deficiency

    Pharmacoepidemiology and Drug Safety

    Volume 1, Issue 6, November/December 1992, Pages: 351–352, C. M. P. W. Mandigers, J. Derksen, F. P. Kroon and Dr. R. H. B. Meyboom

    Version of Record online : 12 JAN 2006, DOI: 10.1002/pds.2630010608